Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Renal Cancer
- Interventions
- Drug: 124IcG250
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01582204
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Conditions
- Lung Cancer
- Interventions
- Drug: LDE225, Etoposide and Cisplatin
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01579929
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
- Conditions
- Advanced Lung Cancer
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT01579994
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
- Conditions
- Cancer
- Interventions
- Behavioral: survey, questionaire
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 360
- Registration Number
- NCT01579552
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- Drug: AG-013736 (AXITINIB)
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT01558661
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- Behavioral: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 257
- Registration Number
- NCT01558648
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
- Conditions
- Esophageal Cancer
- Interventions
- Device: wireless pulse oximeter (Wipox)
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 166
- Registration Number
- NCT01551433
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
- Conditions
- Metastatic Transitional Cell Carcinoma of the Urothelium
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01551030
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT01543659
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer
- Conditions
- Prostatic AdenocarcinomaProstate Cancer
- Interventions
- Drug: androgen deprivation therapy
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT01542021
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States